Mark J. Ratain to Practice Guidelines as Topic
This is a "connection" page, showing publications Mark J. Ratain has written about Practice Guidelines as Topic.
Connection Strength
0.564
-
Accelerated Approval Program Versus NCCN Guidelines as Mechanisms for Early Drug Access. J Natl Compr Canc Netw. 2024 08; 22(6):435-436.
Score: 0.145
-
Ethical Framework for Including Research Biopsies in Oncology Clinical Trials: American Society of Clinical Oncology Research Statement. J Clin Oncol. 2019 09 10; 37(26):2368-2377.
Score: 0.102
-
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems. Clin Pharmacol Ther. 2017 Sep; 102(3):502-510.
Score: 0.088
-
Meaningful use of pharmacogenetics. Clin Pharmacol Ther. 2014 Dec; 96(6):650-2.
Score: 0.074
-
Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clin Cancer Res. 2014 Aug 15; 20(16):4210-7.
Score: 0.073
-
The investigational drug steering committee. Clin Adv Hematol Oncol. 2007 Oct; 5(10):779-80.
Score: 0.045
-
Analyzing the clinical actionability of germline pharmacogenomic findings in oncology. Cancer. 2018 07 15; 124(14):3052-3065.
Score: 0.024
-
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res. 2010 Mar 15; 16(6):1764-9.
Score: 0.013